. In an expansion phase, patients with genetically unselected locally advanced or metastatic pancreatic cancer were randomised 2 : 1 to the tolerated olaparib capsule combination dose or gemcitabine alone (1000 mg/m 2 ).
introduction
In tumours with deficiencies in homologous recombination (HR), poly(adenosine diphosphate [ADP]-ribose) polymerase inhibition (PARPi) is thought to lead to the accumulation of single-strand breaks in DNA, which are converted into doublestrand breaks (DSBs) during replication. DSBs cannot be accurately repaired and result in cell death, a concept known as synthetic lethality [1] . BRCA2 defects and other HR repair deficiencies have been reported in a small but significant proportion (5%-7%) of patients with pancreatic cancers [2] .
Olaparib (Lynparza™) is an oral PARP inhibitor that induces lethality in tumours with HR deficiencies, such as BRCA mutations (BRCAm) [3] . Monotherapy with olaparib has yielded significant clinical benefit in patients with BRCAm [3, 4] . Preclinical studies have shown that PARPi potentiates the effects of DNA-damaging agents [5] . In mice bearing human pancreatic tumour xenografts, PARPi with gemcitabine significantly reduced tumour weight and increased survival [6] . Olaparib in combination with gemcitabine may increase clinical benefit in pancreatic cancer when compared with gemcitabine monotherapy.
Olaparib monotherapy (capsule formulation) is generally well tolerated at doses up to 400 mg twice daily (b.i.d.) using a continuous schedule [3] . However, olaparib combined with chemotherapeutic agents has been associated with increased haematological toxicity [7] . This phase I study was designed to determine the safety, tolerability, and maximum tolerated dose (MTD) of olaparib combined with gemcitabine in patients with advanced solid tumours. Safety and efficacy of the MTD of olaparib (capsules) and gemcitabine in chemotherapy-naïve patients with locally advanced and metastatic pancreatic cancer was evaluated in a randomised dose-expansion phase. methods patients Eligible patients were aged ≥18 years with: clinical or radiological evidence of disease; Eastern Cooperative Oncology Group performance status ≤2; life expectancy ≥12 weeks; adequate bone marrow, hepatic, and renal function. For dose escalation with the capsule formulation, patients had a histologically or cytologically confirmed malignant solid tumour refractory to standard therapy or for which gemcitabine was a potential treatment option. In the tablet cohort of the dose-escalation phase and the dose-expansion phase (capsule), eligible patients had histologically or cytologically confirmed adenocarcinoma of the pancreas with locally advanced or metastatic disease, irrespective of genetic status. For the capsule dose-escalation phase, prior chemotherapy (including gemcitabine) was not allowed within 4 weeks before the start of study treatment; patients who had received >2 courses of prior chemotherapy were excluded from the study. For the tablet doseescalation phase and the dose-expansion (capsule) phase, no prior chemotherapy was allowed. All patients provided written informed consent.
study design
Phase I, open-label, multicentre study comprising two phases: dose-escalation phase to establish the MTD of continuous or intermittent olaparib dosing (capsule) in combination with gemcitabine; dose-expansion phase, where the selected combination dose (olaparib capsule plus gemcitabine) was compared with gemcitabine alone to further establish safety and efficacy in patients with locally advanced or metastatic pancreatic cancer. A separate dose-escalation evaluation assessed olaparib tablet formulation in combination with gemcitabine to determine a tablet dose for future use (supplementary Appendix, available at Annals of Oncology online). The tablet formulation delivers the therapeutic dose in fewer, smaller dose units versus the capsule, reducing the number of pills required. All patients received 28-day treatment cycles of olaparib in combination with gemcitabine, or gemcitabine alone. Patients received treatment as long as it was tolerable without disease progression. The institutional review boards/independent ethics committees of all investigational sites approved the protocol. The study was carried out in accordance with the Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on Bioethics [8] .
dose-escalation phase. over three cohorts, together with 800 mg/m 2 of gemcitabine (unless a DLT occurred). MTD was defined as the dose level below that which caused DLTs in ≥2 patients in a cohort. In the continuous dosing schedule, olaparib was administered for 1 week (on days −7 to −5 and day −4) before the first cycle of chemotherapy to allow samples to be taken for assessment of olaparib and gemcitabine pharmacokinetics (PK).
Patients in the tablet-escalation phase received olaparib once daily on days 1-14. dose-expansion phase. The MTD determined the olaparib/gemcitabine dose combination used in the expansion phase. Patients in the combination arm received intermittent olaparib (capsule) b.i.d. for all cycles. In the doseexpansion phase, gemcitabine was administered on days 1, 8, 15 (all cycles), and day 22 in cycle 1. The dose-expansion phase was randomised in an unblinded 2 : 1 ratio (combination : gemcitabine alone). The stratification for randomisation was based on disease stage and locally advanced or metastatic disease.
study end points and assessments
The primary objective was to determine the safety and tolerability, and establish the MTD, of olaparib in combination with gemcitabine. Safety was monitored throughout the study and assessed according to Common Terminology Criteria for Adverse Events v3, biochemical laboratory tests, vital signs, and physical examination. Secondary objectives were: identification of DLTs of the combination olaparib/gemcitabine; preliminary assessment of antitumour activity [objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and percentage change in tumour size] in patients with locally advanced/metastatic pancreatic cancer; and determination of the plasma PK profile for olaparib and gemcitabine alone and in combination. Tumour size was determined by CT/MRI scans at baseline and following every two cycles. Tumour response was assessed by the investigator according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.0.
Once an appropriate dose of gemcitabine/olaparib combination therapy had been determined, patients with advanced pancreatic cancer were enrolled in the expansion phase. Retrospective BRCA1/2 testing for doseexpansion patients was optional.
statistical analysis
A maximum of 70 patients were to be enrolled in the overall study to determine a tolerable dose of olaparib tablet/capsule formulation in combination with gemcitabine. ORR was compared using Fisher's exact test with difference in ORR [95% confidence interval (CI)] calculated using the Wilson score-based method. PFS and OS were compared using a Cox proportional hazards model with a factor for treatment group [hazard ratio (HR) and 95% CI]. Descriptive statistics were used to describe change in tumour size and safety variables.
results patients
In total, 46 patients were enrolled in the dose-escalation phase; 44 received treatment (intent-to-treat population) ( Figure 1 ) . In the dose-expansion phase, 23 patients were enrolled; 22 received study medication ( Figure 1 ). Demographics and baseline characteristics were generally well balanced ( Table 1 ). The dose-escalation strategy is outlined in Table 2 . The intended study population for the dose-expansion phase was patients with pancreatic cancer who had not received prior chemotherapy; however, two patients with BCRA-positive disease who had tolerability tolerable dosing combination. Four patients (60%) in the doseescalation phase experienced DLTs (continuous cohorts, n = 3; intermittent cohorts, n = 1; Table 2 ). All DLTs resolved following gemcitabine dose modifications. Continuous dosing of olaparib capsules with a gemcitabine dose >600 mg/m 2 was considered non-tolerated following two DLTs [grade 3 increased alanine aminotransferase (ALT) and grade 3 neutropenia and persistent fatigue] in patients receiving continuous olaparib 100 mg b.i.d. capsules and gemcitabine 800 mg/m 2 ( Table 2) . Intermittent olaparib dosing was explored. Olaparib 100 mg b.i.d. (capsule: days 1-14) in combination with gemcitabine 600 mg/m 2 was considered to have acceptable tolerability and selected for the expansion phase. A dose schedule of 200 mg b.i.d. intermittent olaparib (capsule) with gemcitabine 600 mg/m 2 was not considered tolerable for the expansion phase because of dose delays/reductions to both treatments, mainly relating to haematological adverse events (AEs). adverse events. The predominant treatment-emergent AEs (TEAEs) encountered in olaparib capsule cohorts are shown in Table 3 . Overall, 38/47 (81%) patients treated with olaparib capsule and gemcitabine reported grade ≥3 TEAEs. The most common were haematological toxicities, which occurred in 26/ 47 (55%) patients.
Twenty-nine (44%) patients reported serious AEs (SAEs) during the study. The most common were dyspnoea (n = 4; 14%), abdominal pain (n = 3; 10%), vomiting (n = 3; 10%), and deep vein thrombosis (n = 3; 10%). No SAEs were attributed to olaparib alone; six patients had SAEs that were considered to have a causal relationship with combined olaparib/gemcitabine (primarily infections). There were two deaths which were considered by the investigator to be related to both olaparib and gemcitabine dosing modifications. In total, 33/47 (70%) patients treated with olaparib capsules and gemcitabine experienced TEAEs that led to dose interruptions; these were predominantly haematological toxicities (thrombocytopenia: 38%, n = 18; neutropenia: 34%, n = 16). antitumour activity overall response rate. In the dose-escalation phase, ORR was 10% (n = 4/41). In the dose-expansion phase, ORR for the combination was 27% [95% CI 10.9-52.0 (n = 4/15)] compared with 14% [95% CI 2.6-51.3 (n = 1/7)] with gemcitabine alone; the difference was not significant. The sample size in the expansion cohort only included 22 patients with a 2 : 1 randomisation. Details of patients demonstrating an ORR are in supplementary Table S1 , available at Annals of Oncology online.
other secondary end points. In the dose-expansion phase, there were no differences in PFS or OS. Best percentage change in relative tumour size from baseline is shown in Figure 2 . (Table 1 ). In the combination arm, two patients had a BRCA1 mutation and one patient had a BRCA2 mutation (all three patients with BRCAm had metastatic unresectable pancreatic cancer; both patients with BRCA1 mutation had previous breast cancer). Three patients each in the combination and gemcitabine alone arm were known to be BRCA wild type. . High incidences of thrombocytopenia and raised levels of aspartate aminotransferase (AST)/ALT were reported in these groups. These cohorts recruited a higher proportion of refractory solid tumour patients who had received several prior chemotherapy treatments, potentially increasing susceptibility to treatment-induced toxicities. While increases in AST/ALT are not known to be associated with the use of olaparib, transient increases have been reported in a large proportion of patients administered gemcitabine [9] . There were no signals of potential drug-induced liver injury in this study.
Consistent with previous studies of olaparib combined with chemotherapy, most commonly reported AEs included anaemia, neutropenia, and thrombocytopenia [7] . Myelosuppression at rates higher than expected has been reported in studies of PARPi administered in combination with temozolomide [10] . Nabpaclitaxel combined with gemcitabine increased rates of haematological AEs compared with gemcitabine alone in a similar patient population [11] . We also evaluated the olaparib tablet formulation, which allows a smaller number of daily pills. The 100 mg o.d. (intermittent)/600 mg/m 2 gemcitabine dose combination was acceptable and could be considered for future evaluation. In the small PK dataset, no consistent effect on olaparib or gemcitabine In the dose-expansion phase conducted in patients with locally advanced or metastatic pancreatic cancer, no difference in efficacy end points (ORR, PFS, or OS) was observed between treatment cohorts. The numbers in each group for this comparative assessment were small (olaparib/gemcitabine: n = 15; gemcitabine alone: n = 7), there was sub-optimal dosing of gemcitabine, and this part of the study was conducted in a genetically unselected pancreatic cancer patient population. Due to tolerability, the gemcitabine dose of 600 mg/m 2 administered with olaparib was lower than standard doses of gemcitabine monotherapy in this treatment setting. A study of gemcitabine 600 mg/m 2 (initial doses) in combination with radiation in unresectable pancreatic cancer reported a significant improvement in OS compared with gemcitabine alone [12] . The combination of intermittent olaparib 100 mg b.i.d. with 600 mg/m 2 gemcitabine may provide meaningful activity against pancreatic adenocarcinoma.
Phase II trials have shown that olaparib has favourable singleagent antitumour activity in patients with breast and ovarian cancers who have a BRCAm [4] . Mutations in the BRCA genes are associated with an increased risk of pancreatic cancer [13] , and this patient subset may potentially benefit from targeted therapy with PARPi. In our randomised comparative expansion phase, of nine patients for whom BRCAm status was known, three had a BRCAm and were randomised to combination treatment. Although these patients demonstrated good PFS and OS, efficacy comparison with the gemcitabine arm was not possible.
Limitations of the study include small sample sizes in the randomised dose-expansion phase. Furthermore, blinding of investigators to randomised treatment was not possible due to different gemcitabine doses between the randomised arms. Larger studies are needed to explore whether combination therapy that includes olaparib can be used to increase clinical benefits in advanced pancreatic cancer compared with chemotherapy alone. Given the encouraging response observed in previous olaparib trials involving patients with BRCA-mutated cancers, the evaluation of pancreatic cancer patients with BRCAm is important. Results of ongoing olaparib studies (including NCT01078662 and NCT01296763) may provide insight into the clinical relevance of olaparib in this patient population. Data from study NCT01078662 have shown that olaparib monotherapy had benefits in patients with heavily pre-treated BRCA-mutated pancreatic cancer, as well as other tumour types [14] .
In conclusion, the tolerability of olaparib capsules 100 mg b.i.d. (days 1-14) with gemcitabine 600 mg/m 2 (i.v. days 1, 8, and 15 every 4 weeks) appeared to be acceptable, with no unmanageable or unexpected toxicities, and could be considered for evaluation in future studies. Further evaluation of olaparib in pancreatic adenocarcinoma with a BRCAm should be explored based on the known biology of these tumours and the activity of olaparib in other BRCA-mutated tumours. A phase III, randomised, double-blind, placebo-controlled study of maintenance olaparib monotherapy in patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed on first-line platinum-based chemotherapy (NCT02184195) is ongoing.
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